GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medx Health Corp (OTCPK:MDXHF) » Definitions » COGS-to-Revenue

MDXHF (Medx Health) COGS-to-Revenue : 0.61 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Medx Health COGS-to-Revenue?

Medx Health's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.08 Mil. Its Revenue for the three months ended in Dec. 2024 was $0.13 Mil.

Medx Health's COGS to Revenue for the three months ended in Dec. 2024 was 0.61.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Medx Health's Gross Margin % for the three months ended in Dec. 2024 was 38.64%.


Medx Health COGS-to-Revenue Historical Data

The historical data trend for Medx Health's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medx Health COGS-to-Revenue Chart

Medx Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.52 0.53 0.59 0.60

Medx Health Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.70 0.47 0.63 0.61

Medx Health COGS-to-Revenue Calculation

Medx Health's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.208 / 0.344
=0.60

Medx Health's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.081 / 0.132
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medx Health  (OTCPK:MDXHF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Medx Health's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.081 / 0.132
=38.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Medx Health COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medx Health's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Medx Health Business Description

Traded in Other Exchanges
Address
1495 Bonhill Road, Unit 1, Mississauga, ON, CAN, L5T 1M2
Medx Health Corp is engaged in the development, manufacturing, and marketing of skin-related screening tools and phototherapy devices for pain relief and tissue repair. Its two main product lines are; SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and Phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide effective treatment of pain and tissue damage in the rehabilitation market. It derives key revenue from the sale of Phototherapeutic lasers. The company sells its products internationally, of which prime revenue is generated in Canada and the United States.